Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 10/2023

12-09-2023 | Transcatheter Mitral Valve Replacement | Valvular Heart Disease (TL Kiefer, Section Editor)

Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation

Authors: David Meier, Mariama Akodad, Georgios Tzimas, Olivier Muller, Anson Cheung, David A. Wood, Philipp Blanke, Janarthanan Sathananthan, Fabien Praz, Robert H. Boone, John G. Webb

Published in: Current Cardiology Reports | Issue 10/2023

Login to get access

Abstract

Purpose of Review

Mitral and tricuspid regurgitation represents a clinical challenge. They are associated with a poor prognosis, and many patients are not eligible for conventional surgery. Transcatheter therapies have been the focus of numerous studies and devices over the past decade. Here, we provide a summary of current options for transcatheter treatment of these 2 entities.

Recent Findings

Recent studies have demonstrated the benefits of edge-to-edge repair for increasing numbers of patients. Encouraging early results with transcatheter valve replacement are also becoming available.

Summary

To date, transcatheter edge-to-edge repair is currently the first-line transcatheter treatment for both mitral and tricuspid regurgitation for many patients who are not candidates for surgery. A number of transcatheter replacement devices are under development and clinical investigation but, for the most part, their current use is limited to compassionate cases or clinical trials.
Literature
1.
Tung M, Nah G, Tang J, Marcus G, Delling FN. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart 2022;9.
2.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35–71.PubMed
3.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.PubMedCrossRef
4.
Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326–53.PubMedCrossRef
5.
Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037–48.PubMedCrossRef
6.
Scotti A, Munafo A, Adamo M, et al. Transcatheter edge-to-edge repair in COAPT-ineligible patients: incidence and predictors of 2-year good outcome. Can J Cardiol. 2022;38:320–9.PubMedCrossRef
7.
Hausleiter J, Stocker TJ, Adamo M, Karam N, Swaans MJ, Praz F. Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023;18:957–76.PubMedCrossRef
8.
D. Scott Lim HCH, Paul Grayburn, Konstantinos Koulogiannis, Gorav Ailawadi,, Mathew Williams VGN, Katherine H. Chau, Paul Sorajja, Robert L. Smith II,, Mayra Guerrero DD, Juan F. Granada, Michael J. Mack, Martin B. Leon,, Patrick McCarthy. Consensus document on non-suitability for transcatheter mitral valve repair by edge-to-edge therapy. STRUCTURAL HEART 2021;VOL. 5, NO. 3, 227–233.
9.
Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg. 2019;158(86–94): e1.
10.
Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406.PubMedCrossRef
11.
Stone GW, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. Reply N Engl J Med. 2019;380:1980–1.PubMed
12.
Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT Registry. JACC Cardiovasc Interv. 2019;12:1342–52.PubMedCrossRef
13.
•• von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-world outcomes of fourth-generation mitral transcatheter repair: 30-day results from EXPAND G4. JACC Cardiovasc Interv. 2023;16:1463–73. Large all-comers registry of contemporary outcomes of M-TEER using fourth generation MitraClip.CrossRef
14.
Kar S, von Bardeleben RS, Rottbauer W, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND Study. JACC Cardiovasc Interv. 2023;16:589–602.PubMedCrossRef
15.
Szerlip M, Spargias KS, Makkar R, et al. 2-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP Study. JACC Cardiovasc Interv. 2021;14:1538–48.PubMedCrossRef
16.
Mauri V, Sugiura A, Spieker M, et al. Early outcomes of 2 mitral valve transcatheter leaflet approximation devices: a propensity score-matched multicenter comparison. JACC Cardiovasc Interv. 2022;15:2541–51.PubMedCrossRef
17.
Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15:2523–36.PubMedCrossRef
18.
Geis NA, Schlegel P, Heckmann MB, Katus HA, Frey N, Crespo Lopez P, Raake PWJ. One-year results following PASCAL-based or MitraClip-based mitral valve transcatheter edge-to-edge repair. ESC Heart Fail. 2022;9:853–65.PubMedPubMedCentralCrossRef
19.
Luedike P, Riebisch M, Schindhelm F, et al. Impact of mitral valve repair technologies on predictability of post-delivery residual mitral regurgitation. JACC Cardiovasc Interv. 2021;14:2638–40.PubMedCrossRef
20.
Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70:2315–27.PubMedCrossRef
21.
Rogers JH, Asch F, Sorajja P, et al. Expanding the spectrum of TEER suitability: evidence from the EXPAND G4 post approval study. JACC Cardiovasc Interv. 2023;16:1474–85.PubMedCrossRef
22.
Hausleiter J, Lim DS, Gillam LD, et al. Transcatheter edge-to-edge repair in patients with anatomically complex degenerative mitral regurgitation. J Am Coll Cardiol. 2023;81:431–42.PubMedCrossRef
23.
Liu X, Chen M, Han Y, et al. First-in-human study of the novel transcatheter mitral valve repair system for mitral regurgitation. JACC Asia. 2022;2:390–4.PubMedPubMedCentralCrossRef
24.
Khatib D, Neuburger PJ, Pan S, Rong LQ. Transcatheter mitral valve interventions for mitral regurgitation: a review of mitral annuloplasty, valve replacement, and chordal repair devices. J Cardiothorac Vasc Anesth. 2022;36:3887–903.PubMedCrossRef
25.
26.
Anker SD, Starling RC, Khan MS, et al. Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation and severe left ventricular enlargement. JACC Heart Fail. 2021;9:453–62.PubMedCrossRef
27.
Gerosa G, Nadali M, Longinotti L, et al. Transapical off-pump echo-guided mitral valve repair with neochordae implantation mid-term outcomes. Ann Cardiothorac Surg. 2021;10:131–40.PubMedPubMedCentralCrossRef
28.
Regueiro A, Ye J, Fam N, et al. 2-year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10:1671–8.PubMedCrossRef
29.
30.
Cohen DJ, Ludwig S, Piazza N. Transcatheter mitral valve replacement will remain a niche therapy: pros and cons. EuroIntervention. 2023;18:1222–5.PubMed
31.
Alperi A, Granada JF, Bernier M, Dagenais F, Rodes-Cabau J. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:3058–78.PubMedCrossRef
32.
•• Ludwig S, Perrin N, Coisne A et al. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry. EuroIntervention 2023. Largest TMVR registry to date, illustrating clinical benefits but also challenges of TMVR.
33.
Alperi A, Avanzas P, Leon V, et al. Current status of transcatheter mitral valve replacement: systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1130212.PubMedPubMedCentralCrossRef
34.
Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. Eur J Heart Fail. 2022;24:899–907.PubMedCrossRef
35.
Muller DWM, Sorajja P, Duncan A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847–59.PubMedCrossRef
36.
Rodes-Cabau J, Regueiro A, Mack MJ. Transcatheter mitral valve replacement: a need for better patient selection. J Am Coll Cardiol. 2021;78:1860–2.PubMedCrossRef
37.
Ludwig S, Conradi L, Cohen DJ, et al. Transcatheter mitral valve replacement versus medical therapy for secondary mitral regurgitation: a propensity score-matched comparison. Circ Cardiovasc Interv. 2023;16: e013045.PubMedCrossRef
38.
Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12–21.PubMedCrossRef
39.
Makkar R ONW, Whisenant B, et al. Updated 30-Day Outcomes for the U.S. Early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. J Am Coll Cardiol 2019;Sep 1;74(13):B8.
40.
Goel SS, Zuck V, Christy J, Nallamothu N, Jagtap P, Gao J, Goswami NJ. Transcatheter mitral valve therapy with novel supra-annular AltaValve: first experience in the United States. JACC Case Rep. 2019;1:761–4.PubMedPubMedCentralCrossRef
41.
Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418–26.PubMedCrossRef
42.
Alperi A, Dagenais F, Del Val D, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv. 2020;13:2427–37.PubMedCrossRef
43.
Niikura H, Gossl M, Kshettry V, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:196–204.PubMedCrossRef
44.
Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887–98.PubMedCrossRef
45.
Coisne A, Pontana F, Tchetche D, et al. Transcatheter mitral valve replacement: factors associated with screening success and failure. EuroIntervention. 2019;15:e983–9.PubMedCrossRef
46.
Eleid MF, Collins JD, Mahoney P, et al. Emerging approaches to management of left ventricular outflow obstruction risk in transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2023;16:885–95.PubMedCrossRef
47.
Ludwig S, Kalbacher D, Ali WB, et al. Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis. Eur J Heart Fail. 2023;25:399–410.PubMedCrossRef
48.
Al-Tawil M, Butt S, Reap S, et al. Transseptal vs transapical transcatheter mitral valve-in-valve and valve-in-ring implantation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48: 101684.PubMedCrossRef
49.
Guerrero M, Pursnani A, Narang A, et al. Prospective evaluation of transseptal TMVR for failed surgical bioprostheses: MITRAL trial valve-in-valve arm 1-year outcomes. JACC Cardiovasc Interv. 2021;14:859–72.PubMedCrossRef
50.
Whisenant B, Kapadia SR, Eleid MF, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve. JAMA Cardiol. 2020;5:1245–52.PubMedPubMedCentralCrossRef
51.
Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol. 2022;80:2171–83.PubMedCrossRef
52.
Simonato M, Whisenant B, Ribeiro HB, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry. Circulation. 2021;143:104–16.PubMedCrossRef
53.
Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, Tribouilloy C, Benfari G, Michelena H. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62:447–51.PubMedCrossRef
54.
Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840–51.PubMedCrossRef
55.
Dreyfus J, Flagiello M, Bazire B, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. 2020;41:4304–17.PubMedCrossRef
56.
Groger M, Friedl S, Ouerghemmi D et al. TRI-SCORE is superior to EuroSCORE II and STS-Score in mortality prediction following transcatheter edge-to-edge tricuspid valve repair. Clin Res Cardiol 2023.
57.
Vogelhuber J, Tanaka T, Sugiura A et al. Association of TRI-SCORE with clinical outcomes after transcatheter tricuspid valve repair. JACC Cardiovasc Interv 2023.
58.
Lurz P, Stephan von Bardeleben R, Weber M et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021;77:229–239.
59.
Lurz P, Besler C, Schmitz T et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023.
60.
•• Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–42. Pivotal randomized trial on TEER versus medical management for severe TR.PubMedCrossRef
61.
Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. JACC Cardiovasc Interv. 2018;11:407–8.PubMedCrossRef
62.
Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488–95.PubMedCrossRef
63.
Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–56.PubMedCrossRef
64.
Nickenig G, Weber M, Schuler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264–71.PubMedPubMedCentralCrossRef
65.
Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention. 2021;17:809–17.PubMedPubMedCentralCrossRef
66.
Stolz L, Weckbach LT, Hahn RT, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374–6.PubMedCrossRef
67.
Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481–91.PubMedCrossRef
68.
Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471–80.PubMedCrossRef
69.
Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system. EuroIntervention. 2022;18:862–4.PubMedCrossRef
70.
Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021;107:1664–70.PubMedCrossRef
71.
Zhang Y, Lu F, Li W et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention 2022.
72.
Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the tricvalve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366–77.PubMedCrossRef
73.
Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A et al. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention 2023.
74.
Wild MG, Lubos E, Cruz-Gonzalez I, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15: e011302.PubMedCrossRef
75.
Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg 2008;34:402–9; discussion 409.
76.
Dreyfus J, Bohbot Y, Coisne A, et al. Predictive value of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve surgery. Heart. 2023;109:951–8.PubMedCrossRef
77.
McElhinney DB, Aboulhosn JA, Dvir D, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148–57.PubMedCrossRef
78.
Anderson JH, McElhinney DB, Aboulhosn J, et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. JACC Cardiovasc Interv. 2020;13:2012–20.PubMedCrossRef
Metadata
Title
Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation
Authors
David Meier
Mariama Akodad
Georgios Tzimas
Olivier Muller
Anson Cheung
David A. Wood
Philipp Blanke
Janarthanan Sathananthan
Fabien Praz
Robert H. Boone
John G. Webb
Publication date
12-09-2023
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 10/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01954-y

Other articles of this Issue 10/2023

Current Cardiology Reports 10/2023 Go to the issue

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Addressing Barriers for Women with Advanced Heart Failure

Heart Failure (HJ Eisen, Section Editor)

The Effect of EECP on Ischemic Heart Failure: a Systematic Review

Global Cardiovascular Health (L Sperling and D Gaita, Section Editors)

Improving Hypertension Control in Vulnerable Populations Around the World

Ischemic Heart Disease (D Mukherjee, Section Editor)

Sodium Homeostasis and Hypertension

Structural Heart Disease (S Vakamudi, Section Editor)

The Emerging Role of Intracardiac Echocardiography (ICE) in Left Atrial Appendage Closure (LAAC)

Echocardiography (JM Gardin and AH Waller, Section Editors)

Echocardiographic Evaluation of Cardiac Masses

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits